| Eligibility |
Inclusion Criteria:
1. Adult patients (>18 y.o.) who signed informed consent form (ICF) prior to
participation in any study-related activities.
2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
and other study procedures.
3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
4. High-volume metastatic disease documented on bone scan or computed tomography
(CT)/magnetic resonance imaging (MRI) scan, defined as the presence of either visceral
disease and/or at least four bone metastases on bone scan, with at least one of them
beyond spine/pelvis.
5. Life expectancy of = 12 months.
6. Histologically confirmed adenocarcinoma of the prostate without predominance of
small-cell or neuroendocrine features according to American Society of Clinical
Oncology/College of American Pathologists (ASCO/CAP) guidelines based on local testing
on the most recent analyzed biopsy.
Note: Central confirmation of adenocarcinoma is not required for study entry. However,
tissue blocks, or slides, must be submitted to confirm the diagnoses by a
Sponsor-designated central laboratory retrospectively and/or exploratory biomarker
analyses.
7. Willingness and ability to provide tumor paired biopsies during the study
participation in order to perform exploratory studies. At the study entry, the most
recent tumor biopsy since last progression from either metastatic or primary tissues
will be provided. If not feasible, patient eligibility should be evaluated by a
Sponsor's qualified designee.
8. Adequate hematologic and organ function within 28 days before the first study
treatment on Cycle 1 Day 1, defined by the following:
1. Hematological: White blood cell (WBC) count > 3.0 x 109/L; Absolute neutrophil
count (ANC) > 1.5 x 109/L; Platelet count > 100.0 x109/L; Hemoglobin (Hb) > 9.0
g/dL.
Note: Patients receiving growth factors or blood transfusions within 14 days
before obtaining the hematology values at screening will be excluded.
2. Hepatic: Total bilirubin = 1.5 times the upper limit of normal (× ULN) (= 3 x ULN
in the case of Gilbert's disease); Aspartate transaminase (AST) and alanine
transaminase (ALT) = 2.5 × ULN (in the case of liver metastases = 5 × ULN);
Alkaline phosphatase (ALP) = 2.5 × ULN (= 5 × ULN inthe case of liver and/or bone
metastases).
3. Renal: Serum creatinine < 1.5 × ULN or creatinine clearance = 30 mL/min based on
Cockcroft-Gault glomerular filtration rate estimation.
4. Coagulation: International normalized ratio (INR) and activated partial
thromboplastin time (aPTT) = 1.5 x ULN unless on medication known to alter INR
and/or aPTT.
5. Nutritional status: Serum Albumin = 2.8 g/dL.
9. Bisphosphonates or denosumab dosage must have been stable for at least 4 weeks before
Day 1 for patients receiving these therapies.
10. Patients must agree to use a condom when is engaged in sexual activity with a pregnant
woman during the treatment period and for at least 90 days after last dose of
enzalutamide or at least 120 days after last dose of talazoparib (PF-06944076),
whichever occurs later. Patients must also agree to use an additional highly effective
form of contraception or two effective contraceptive methods, when is engaged in
sexual intercourse with a woman of childbearing potential during the treatment period
and for at least 90 days after last dose of enzalutamide or at least 120 days after
last dose of talazoparib (PF-06944076), whichever occurs later.
11. Must agree to refrain to donate sperm during the treatment period and for at least 90
days after last dose of enzalutamide or at least 120 days after last dose of
talazoparib (PF-06944076), whichever occurs later.
12. PSA = 4 ng/mL at diagnosis or before starting ADT therapy.
Exclusion Criteria:
1. Prior treatment with enzalutamide, apalutamide, darolutamide or abiraterone acetate.
2. History of malabsorption syndrome or other condition that would interfere with enteral
absorption or results in the inability or unwillingness to swallow pills.
3. Known hypersensitivity to recombinant proteins, or any excipient contained in the drug
formulation for talazoparib (PF-06944076) and enzalutamide.
4. Prior systemic therapy for metastatic prostate cancer (mPCa). Note: Initiation of
androgen deprivation therapy (ADT) within 4 weeks prior to study entry would be
allowed (with or without first-generation antiandrogens), providing a tumor biopsy
sample was taken prior to initiation of ADT is made available for biomarker studies
and upon approval by the sponsor. If patient was started on first-generation
antiandrogens, these would be discontinued on prior to randomization.
Note: Patients relapsing after having received an ADT-based regimen in neoadjuvant or
adjuvant setting will be suitable for the study if metastatic progression occured
while on non-castrate testosterone levels or at least 12 months after discontinuation
of ADT.
5. Treatment with approved or investigational cancer therapy within 28 days (or 5
half-lives of the drug- whichever is longer) prior to initiation of study treatment.
6. Known or suspected brain metastases or active leptomeningeal disease.
7. Symptomatic or impending spinal cord compression or cauda equina syndrome.
8. Subject has a history of seizure or any condition that may predispose to seizure (i.e.
prior significant brain trauma, brain vascular malformations, ...), or subjects that
have had unexplained loss of consciousness or transient ischemic attacks within 1 year
prior to scheduled Day 1 of treatment.
9. Therapeutic radiation therapy within 14 days (seven days for limited-field palliative
radiotherapy) prior to study enrolment, or patients who have not recovered from
radiotherapy-related toxicities to grade = 1 according to National Cancer Insitute ´s
Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v.)5.0.
10. Major surgery (defined as requiring general anesthesia) or significant traumatic
injury within 14 days of start of study drugs, or patients who have not recovered from
the side effects of any major surgery.
11. History of another malignancy within three years of study enrollment with the
exception of carcinoma in situ, non-melanoma skin carcinoma, or American Joint
Committee on Cancer stage 0 or stage 1 cancer that has a remote probability of
recurrence in the opinion of the investigator and the Sponsor's Medical Monitor is
required, or any concurrent malignancy for which the patient is receiving therapy.
12. Active uncontrolled infection at the time of enrollment.
13. Congenital long QT syndrome or Electrocardiogram (ECG) at screening with QT interval
corrected using Fridericia's formula (QTcF) > 500 milliseconds.
14. Patients with clinically significant cardiovascular disease including but not limited
to any of the following:
1. Stroke, transient ischemic attack, unstable angina pectoris, or documented
myocardial infarction within 12 months prior to study entry.
2. Symptomatic pericarditis or clinically significant pericardial effusion or
myocarditis.
3. Documented congestive heart failure (New York Heart Association functional
classification III- IV).
4. Uncontrolled, persistent hypertension defined as systolic blood pressure > 170
mmHg or diastolic blood pressure > 100 mmHg.
15. Patients have any of the following cardiac conduction abnormalities:
1. Ventricular arrhythmias except for benign premature ventricular contractions.
2. Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled
with medication.
3. Conduction abnormality requiring a pacemaker.
4. Other cardiac arrhythmia not controlled with medication.
16. Patients have any other concurrent severe and/or uncontrolled medical condition that
would, in the Investigator's judgment contraindicate patient participation in the
clinical study.
17. Treatment with estrogens, cyprotoerone acetate or glucocorticoids (at a dose greater
than the equivalent to 10 mg/day of prednisone) in the 4 weeks prior to scheduled Day
1 of treatment.
18. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
patients who are employees of the trial sponsor, including their family members,
directly involved in the conduct of the study.
19. Concurrent participation in other clinical trial, except other translational studies
or observational studies (defined as those with no therapeutic intervention).
|
